Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 18.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers, Election of Directors, Appointment of Certain Officers; |
| 14.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers, Election of Directors, Appointment of Certain Officers; |
| 15.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | .01 of Form 8-K, the information set forth under Item 5.02 of this Current Report on Form 8-K regarding the executive of |
| 18.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | K is incorporated herein by reference. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; A |
| 22.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offi |
| 03.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offi |
Stammdaten
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Unternehmen & Branche
| Name | Tvardi Therapeutics, Inc. |
|---|---|
| Ticker | TVRD |
| CIK | 0001346830 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 28,6 Mio. USD |
| Beta | 0,15 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -18,214,000 | -3.26 | 32,073,000 | 20,946,000 | |
| 2025-09-30 | 10-Q | -5,527,000 | -0.59 | 39,021,000 | 27,866,000 | |
| 2025-06-30 | 10-Q | 4,167,000 | -1.00 | 43,750,000 | 32,927,000 | |
| 2025-03-31 | 10-Q | 2,569,000 | -9,579,000 | -3.22 | 38,947,000 | -100,625,000 |
| 2024-12-31 | 10-K | 7,137,000 | -29,397,000 | -11.42 | 35,199,000 | -91,131,000 |
| 2024-09-30 | 10-Q | 2,556,000 | -5,513,000 | -2.14 | 51,329,000 | -78,503,000 |
| 2024-06-30 | 10-Q | 991,000 | -6,975,000 | -2.71 | 72,495,000 | -73,070,000 |
| 2024-03-31 | 10-Q | 2,135,000 | -4,202,000 | -20.24 | 90,099,000 | -66,174,000 |
| 2023-12-31 | 10-K | 20,968,000 | -118,513,000 | -26.26 | 125,844,000 | -62,058,000 |
| 2023-09-30 | 10-Q | 4,866,000 | -28,032,000 | -0.52 | 115,338,000 | 85,642,000 |
| 2023-06-30 | 10-Q | 6,933,000 | -31,479,000 | -0.58 | 134,389,000 | 108,932,000 |
| 2023-03-31 | 10-Q | 6,165,000 | -26,665,000 | -0.49 | 153,276,000 | 136,598,000 |
| 2022-12-31 | 10-K | 41,867,000 | -85,474,000 | -19.12 | 182,237,000 | 158,779,000 |
| 2022-09-30 | 10-Q | 10,813,000 | -23,180,000 | -0.43 | 213,509,000 | 184,820,000 |
| 2022-06-30 | 10-Q | 23,003,000 | -4,206,000 | -0.08 | 226,572,000 | 204,422,000 |
| 2022-03-31 | 10-Q | 4,790,000 | -27,749,000 | -0.52 | 223,866,000 | 204,115,000 |
| 2021-12-31 | 10-K | 23,028,000 | -88,441,000 | -1.74 | 247,056,000 | 227,522,000 |
| 2021-09-30 | 10-Q | 20,272,000 | -1,013,000 | -0.02 | 225,092,000 | 207,191,000 |
| 2021-06-30 | 10-Q | 1,935,000 | -30,745,000 | -0.61 | 221,454,000 | 203,466,000 |
| 2021-03-31 | 10-Q | 1,935,000 | -23,301,000 | -0.47 | 250,228,000 | 230,459,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.